Systematic cryoprotectant screening to preserve LNP particle integrity, payload retention, and freeze–thaw recovery.
Lipid nanoparticles are highly sensitive to freezing stress, ice–liquid interface exposure, cryo-concentration, osmotic shifts, and repeated temperature excursions during storage or shipment. Without a suitable cryoprotectant system, LNPs may show particle size growth, elevated PDI, visible or subvisible aggregation, payload leakage, reduced RNA integrity, and poor recovery after thawing. BOC Sciences provides specialized LNP Cryoprotectant Screening Services to help formulation teams identify protection strategies for frozen storage, freeze–thaw handling, transport simulation, and long-term preservation. Our service evaluates sucrose, trehalose, maltose, mannitol, glycerol, amino acids, polymers, surfactant-assisted systems, and customized excipient combinations using orthogonal analytical readouts. By integrating particle characterization, payload retention analysis, recovery assessment, and stability tracking, we help researchers select cryoprotectant conditions that maintain LNP structure and support reliable downstream formulation development.
BOC Sciences provides a structured LNP cryoprotectant screening platform for frozen storage, freeze–thaw handling, lyophilization development, transport simulation, and long-term preservation studies.
We build candidate libraries according to the LNP composition, payload type, intended storage condition, and expected stress pathway. Each candidate is evaluated not only for particle protection but also for compatibility with analytical assays and downstream formulation handling.
Cryoprotectant concentration strongly affects LNP stability, osmotic stress, viscosity, reconstitution performance, and payload retention. We design concentration gradients to determine the minimum effective protection threshold and the upper concentration limit suitable for practical formulation use.
For LNP projects requiring freeze-dried formats, cryoprotectant selection must be aligned with annealing strategy, collapse behavior, glass transition properties, cake structure, and reconstitution performance. BOC Sciences integrates excipient screening with lyophilization-relevant evaluation to identify conditions that protect both particle structure and payload integrity.
The best cryoprotectant for one LNP system may fail in another because lipid composition, PEG-lipid density, buffer matrix, payload chemistry, and particle concentration all influence freezing behavior. We evaluate cryoprotectant compatibility across the complete LNP formulation rather than treating the protectant as an isolated additive.
A successful cryoprotectant is not selected by appearance alone. BOC Sciences applies a multi-attribute assessment framework to determine whether a candidate excipient preserves the colloidal, structural, and payload-related properties of LNPs after freezing, thawing, and storage.
Identify cryoprotectant conditions that preserve particle integrity, reduce aggregation, and maintain payload retention during frozen storage and transport.
BOC Sciences supports multiple cryoprotectant categories for LNP frozen storage, freeze–thaw handling, lyophilization development, transport simulation, and long-term stability evaluation. Candidates can be screened alone, in concentration gradients, or as combination systems to compare particle size retention, aggregation control, payload retention, recovery, and reconstitution behavior.
| Cryoprotectant Type | Representative Candidates and Screening Focus |
|---|---|
| Sugars and Sugar Alcohols | Sucrose, trehalose, maltose, lactose, glucose, mannitol, and sorbitol are screened to preserve LNP hydration, reduce ice-induced membrane stress, maintain particle size, and improve post-thaw or post-reconstitution recovery. |
| Synthetic Polymers | PVP, PEG, poloxamer-type systems, dextran derivatives, and related polymers are evaluated when sugar-only systems cannot sufficiently suppress aggregation, size drift, or poor redispersion in high-concentration LNP formulations. |
| Amino Acids and Zwitterionic Excipients | Glycine, proline, arginine, histidine, methionine, betaine, taurine, and similar systems are tested to improve colloidal robustness, buffer compatibility, and payload protection during freezing and thawing. |
| Polyols | Glycerol, propylene glycol, ethylene glycol, and related polyols are assessed for cryostress reduction, osmotic adjustment, viscosity impact, freeze–thaw recovery, and compatibility with downstream analysis. |
| Proteins and Serum-Derived Systems | Albumin, gelatin, serum-containing matrices, and protein-assisted systems may be explored for research formulations requiring additional interfacial protection or biomolecule-compatible stabilization. |
| Inorganic Salts and Buffer Systems | Sodium chloride, phosphate, citrate, acetate, Tris, histidine, and other buffer systems are compared to understand how ionic strength, pH, and buffer composition affect LNP cryostability. |
LNP formulations often fail during freezing for reasons that are not visible from a single endpoint test. Our screening studies are designed to identify the source of instability and compare practical protection strategies.
✔ Particle Size Growth After Thawing
Ice formation and freeze concentration can promote LNP–LNP interaction, leading to larger hydrodynamic diameter and higher PDI. We screen cryoprotectant type, concentration, and thawing protocol to identify conditions that minimize size drift.
✔ Aggregation During Transport
Temperature excursions during shipment can trigger reversible or irreversible aggregation. We simulate transport-relevant stress patterns and compare excipient systems that support redispersion and particle uniformity.
✔ Payload Leakage and EE Loss
Freezing stress may disturb lipid packing and increase cargo accessibility. We measure encapsulated versus free payload and can integrate LNP encapsulation efficiency optimization when the formulation requires deeper adjustment.
✔ Poor Freeze–Thaw Recovery
Some formulations retain acceptable size but lose recoverable particle concentration or total payload. We calculate recovery from multiple markers to distinguish true loss from measurement interference.
✔ Buffer and Cryoprotectant Incompatibility
The same cryoprotectant can perform differently in Tris, histidine, citrate, acetate, or other buffer systems. We compare buffer–excipient matrices to find conditions that preserve particle and payload attributes together.
✔ Analytical Interference from Excipients
Sugars, polymers, and surfactants may affect fluorescence, chromatography, or particle counting. We include matrix controls and method checks to ensure the selected cryoprotectant does not create misleading stability data.
We review LNP composition, payload type, concentration, buffer matrix, target storage condition, and known instability issues. A screening plan is then designed around frozen storage, freeze–thaw cycling, transport simulation, or long-term stability tracking.
Candidate cryoprotectants are prepared as single excipients, concentration gradients, or blend systems. We can include sucrose, trehalose, maltose, mannitol, glycerol, amino acids, polymers, surfactant-assisted systems, and custom combinations.
Samples are exposed to defined freezing, thawing, and storage conditions. Depending on the project, we compare one-cycle stress, repeated freeze–thaw cycles, frozen holding periods, temperature excursions, or long-term monitoring intervals.
We rank cryoprotectant conditions using particle size, PDI, aggregation profile, zeta potential, payload retention, recovery percentage, and assay compatibility. The final report highlights lead conditions and recommended next-step formulation studies.
Challenge: A research team developing an ionizable mRNA LNP observed a hydrodynamic diameter increase from approximately 95 nm to more than 150 nm after three freeze–thaw cycles. The formulation also showed broader PDI and a measurable decrease in encapsulated RNA signal after thawing.
Diagnosis: Initial testing suggested that the lipid ratio was not the only cause. The original buffer had limited protection against freeze concentration, and the LNPs were sensitive to the thawing profile. A single 5% sucrose condition reduced visible aggregation but did not sufficiently protect payload retention.
Solution: BOC Sciences designed a cryoprotectant matrix containing 5–20% sucrose, 5–20% trehalose, sucrose–trehalose blends, and selected amino acid-assisted conditions in two compatible buffer systems. Each condition was tested after one, three, and five freeze–thaw cycles. DLS, PDI, zeta potential, RiboGreen-based encapsulation assessment, and RNA integrity analysis were used to compare performance. The lead condition was a mixed disaccharide system that maintained particle size within a narrow post-thaw range and reduced PDI broadening compared with single-sugar controls.
Result: The optimized cryoprotectant condition maintained more than 90% encapsulated RNA signal after three freeze–thaw cycles and reduced post-thaw size growth to less than 10% relative to the pre-freeze sample, supporting the client's selection of a more robust frozen-storage formulation.
Challenge: A siRNA LNP formulation designed for targeted delivery showed acceptable initial size and encapsulation, but particle recovery dropped sharply after a simulated frozen transport cycle. The sample appeared clear after thawing, yet DLS revealed a secondary large-particle population.
Diagnosis: The formulation was sensitive to interfacial stress and concentration gradients during freezing. Sucrose alone improved size retention but did not fully restore recoverable particle concentration. Mannitol-containing conditions showed inconsistent redispersion, indicating that crystallization-associated stress might be contributing to recovery loss.
Solution: We compared sucrose, trehalose, glycerol-assisted systems, PVP-containing blends, and low-level surfactant-assisted conditions under a defined freeze–hold–thaw transport model. Analytical readouts included particle size distribution, PDI, zeta potential, siRNA encapsulation retention, concentration recovery, and post-thaw redispersion after gentle mixing. A trehalose-based blend with a polymeric stabilizer provided the best balance of low aggregation, high payload retention, and practical sample handling.
Result: The selected condition improved post-thaw particle recovery from below 70% to above 90%, eliminated the large-particle shoulder in the DLS profile, and preserved siRNA encapsulation within the predefined project acceptance window.
LNP-Specific Formulation InsightWe understand how ionizable lipids, helper lipids, cholesterol, PEG-lipids, payload chemistry, and buffer composition influence cryostability. Screening designs are customized rather than copied from generic nanoparticle protocols.
Multi-Attribute CharacterizationOur workflow integrates lipid nanoparticle characterization with payload and recovery testing, providing a more complete picture than size data alone.
Cryoprotectant Product CoverageBOC Sciences can support screening with common and advanced cryoprotectant candidates, including sucrose, trehalose, maltose, mannitol, glycerol, amino acids, polymers, and customized excipient blends.
Payload-Aware Stability TestingWe do not evaluate the carrier alone. RNA, DNA, peptide, protein, antigen, and small-molecule payload retention can be measured to ensure the selected condition protects the complete LNP system.
Connection to Process OptimizationWhen cryostability problems originate from particle formation parameters, our team can connect cryoprotectant data with LNP process optimization to improve formulation robustness from preparation to storage.
LNP cryoprotectant screening is essential because lipid nanoparticles can undergo particle aggregation, membrane fusion, payload leakage, and reduced nucleic acid protection during freezing, thawing, or lyophilization. For mRNA-LNP, siRNA-LNP, and other nucleic acid delivery systems, even a small shift in particle size, PDI, encapsulation efficiency, or RNA accessibility may affect formulation performance. Screening helps identify whether sucrose, trehalose, mannitol, or mixed excipient systems can preserve LNP structure during low-temperature stress. BOC Sciences designs screening studies around formulation-specific risks, including lipid composition, buffer environment, payload type, initial particle size, and intended storage condition, enabling researchers to select a cryoprotectant strategy based on comparative data rather than assumption.
Common cryoprotectants for LNP lyophilization include sucrose, trehalose, mannitol, sorbitol, and selected combinations of sugars and polyols. Sucrose and trehalose are frequently evaluated because they can form an amorphous glassy matrix and help reduce particle contact during freezing and drying. Mannitol may improve cake appearance in some formulations, but its crystallization behavior can reduce protection if not properly balanced. Because LNP stability depends on ionizable lipid structure, helper lipids, PEG-lipid content, nucleic acid cargo, and buffer salts, no single cryoprotectant works universally. A rational screening plan should compare different excipient types, concentration gradients, and combinations while monitoring particle size, PDI, encapsulation retention, redispersibility, and payload integrity.
LNP stability after freeze-thaw is typically evaluated by comparing pre-freeze and post-thaw attributes, including hydrodynamic diameter, PDI, zeta potential, visible aggregation, encapsulation efficiency, free nucleic acid content, and recovery after gentle mixing. For mRNA or siRNA LNPs, fluorescence dye accessibility assays, gel-based nucleic acid integrity analysis, and functional expression or silencing-related assays may also be used when appropriate for the research objective. A successful cryoprotectant should limit particle growth, maintain a narrow size distribution, preserve encapsulated payload, and support consistent redispersion. BOC Sciences can structure freeze-thaw studies with multiple cycles, controlled temperature conditions, and parallel comparison of excipient systems to distinguish temporary reversible changes from formulation-damaging instability.
LNP aggregation during freezing is mainly caused by ice crystal formation, freeze concentration of salts and excipients, local pH shifts, osmotic stress, and reduced spacing between particles as water crystallizes. These stresses can disturb the lipid membrane, weaken colloidal repulsion, promote particle-particle contact, and increase the risk of irreversible fusion. LNPs carrying nucleic acids may also show increased RNA exposure if the lipid shell is disrupted. Cryoprotectants such as sucrose and trehalose can reduce these risks by replacing water interactions and forming a protective amorphous matrix, but their effectiveness depends strongly on concentration, cooling profile, buffer composition, and LNP formulation design. Therefore, aggregation analysis should be linked with both physical characterization and payload retention data.
BOC Sciences supports LNP cryoprotectant optimization through systematic screening of excipient type, concentration, buffer compatibility, freeze-thaw response, lyophilization behavior, and post-reconstitution nanoparticle quality. Instead of testing a single cryoprotectant condition, we can build a comparative matrix covering sucrose, trehalose, mannitol, mixed protectants, and formulation-specific concentration ranges. Evaluation can include particle size, PDI, zeta potential, encapsulation efficiency, RNA accessibility, visual appearance, reconstitution behavior, and short-term storage tracking. When instability appears, such as particle growth, incomplete rehydration, or payload leakage, our team analyzes the pattern of failure and adjusts excipient ratio or process conditions accordingly. This helps drug development teams identify a more robust LNP preservation strategy for research-stage formulation development.
